Abstract 1505: Radiogenomics defines key genomic network driving GBM invasion
2016
Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA
PURPOSE
Clinical care and outcome in Glioblastoma (GBM) remains challenging due to the tumor's invasive grwoth. To establish personalized treatment options in GBM, discovery of genetic mechanisms essential for the tumor's invasion is needed. We have previously described radiogenomic approaches to diagnose gene networks non invasively by analyzing genomic data from TCGA. The purpose of the current reseach is to identify a genetic network that drives GBM invasion and can be targeted specifically.
METHOD AND MATERIALS
Using Kaplan-Meier statistics, the data of the two independent databases TCGA and REMBRANDT were used to validate the genetic netowork's impact on clinical outcome. The genes’ staus was assessed in a panel of human glioma stem cells (GSCs) and conventional proneural, classical and mesenchymal GBM cell lines using RT-PCR. Differentiation potential (Tuj1+ve, S100A+ve, and GFAP+ve), self-renewal (limiting dilution assays), invasion (Boyden chamber) and proliferation (BrdU) were assessed. Gain (lentiviral vectors) and loss (SMARTchoice Inducible shRNA) of function experiments were performed. Orthotopic xenograft models (nude mice) were used to characterize the genes impact in vivo. Potential FDA approved therapeutics were identified using connectivity map.
RESULTS
Texture analysis based on radiogenomics significantly predicted the genes responsible for invasion of GBM in a non-invasive manner. Invasion in both, in vitro and in vivo was significantly decreased upun downregulation of this gene network. Transcriptome micro-array analysis showed that an upregulation of the described genes results in class switching from proneural to mesenchymal sub-types. Cmap derived therapeutics could significantly inhibit the gene network's activitiy and hence invasion.
CONCLUSION
The describend genes could be essential drivers of molecular subtypes and invasion in GBM. The therapeutics defined with cmap offer a targetted therapy to adress these key features of GBM pathogenesis. Noninvasive radiogenomics-based identification of tumor subgroups and potential treatment approaches can significantly contribute to personalized therapy.
CLINICAL RELEVANCE/APPLICATION
The described gene network seems to be key for GBM pathogenesis. Noninvasive, radiogenomics-based subgroup identification and specific novel treatment approaches can significanty contribution to personalized GBM therapy.
Citation Format: Rivka R. Colen, Markus Luedi, Sanjay K. Singh, Islam Hassan, Joy Gumin, Erik P. Sulman, Frederick F. Lang, Pascal O. Zinn. Radiogenomics defines key genomic network driving GBM invasion. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1505.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI